aleta biotherapeutics logo

Aleta Biotherapeutics

Aleta is an immuno-oncology company focused on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted, including some currently intractable solid tumours.

Aleta is a Advent Life Science investment company and was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.aletabio.com
Founded2015
Disease Focus
Development StageTechnology
STOCK CODENon Listed
Address
27 Strathmore Rd, Natick, 1746
Massachusetts
United States
Email
Contact Number
+1 233-678-90

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Aleta Bio has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity. CAR19 cellular therapeutics benefit from interaction with bona fide antigen-presenting B cells (both normal and malignant). The integration of fusion protein modules into CAR19 lentiviral constructs endows CACR19s with novel antigen recognition properties. These highly potent CARjacked CAR19s recognize both CD19 (directly) and novel antigens (redirected) enabling efficient cytotoxicity against diverse tumor types.